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Surfactant lung delivery with LISA and InSurE in adult rabbits
with respiratory distress
Francesca Ricci1, Ilia Bresesti2, Paola Azzurra Maria LaVerde2, Fabrizio Salomone1, Costanza Casiraghi1, Arianna Mersanne1,
Matteo Storti1, Chiara Catozzi1, Laura Tigli1, Riccardo Zecchi3, Pietro Franceschi4, Xabier Murgia5, Manuela Simonato6,7, Paola Cogo8,
Virgilio Carnielli9 and Gianluca Lista2
BACKGROUND: In preterm infants, InSurE (Intubation–Surfactant–Extubation) and LISA (less invasive surfactant administration)
techniques allow for exogenous surfactant administration while reducing lung injury associated with mechanical ventilation.
We compared the acute pulmonary response and lung deposition of surfactant by LISA and InSurE in surfactant-depleted adult
rabbits.
METHODS: Twenty-six spontaneously breathing surfactant-depleted adult rabbits (6–7 weeks old) with moderate RDS and
managed with nasal continuous positive airway pressure were randomized to 3 groups: (1) 200 mg/kg of surfactant by InSurE; (2)
200mg/kg of surfactant by LISA; (3) no surfactant treatment (Control). Gas exchange and lung mechanics were monitored for 180
min. After that, surfactant lung deposition and distribution were evaluated monitoring disaturated-phosphatidylcholine (DSPC) and
surfactant protein C (SP-C), respectively.
RESULTS: No signs of recovery were found in the untreated animals. After InSurE, oxygenation improved more rapidly compared to
LISA. However, at 180’ LISA and InSurE showed comparable outcomes in terms of gas exchange, ventilation parameters, and lung
mechanics. Neither DSPC in the alveolar pool nor SP-C signal distributions in a frontal lung section were significantly different
between InSurE and LISA groups.
CONCLUSIONS: In an acute setting, LISA demonstrated efficacy and surfactant lung delivery similar to that of InSurE in surfactant-
depleted adult rabbits.
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IMPACT:
● Although LISA technique is gaining popularity, there are still several questions to address. This is the first study comparing LISA
and InSurE in terms of gas exchange, ventilation parameters, and lung mechanics as well as surfactant deposition and
distribution.
● In our animal study, three hours post-treatment, LISA method seems to be as effective as InSurE and showed similar surfactant
lung delivery.
● Our findings provide some clarifications on a fair comparison between LISA and InSurE techniques, particularly in terms of
surfactant delivery. They should reassure some of the concerns raised by the clinical community on LISA adoption in
neonatal units.
INTRODUCTION
Preterm infants are at high risk for respiratory distress syndrome
(RDS), mainly due to the immaturity of the lungs, including
ineffective surfactant production and metabolism.1,2 RDS has been
traditionally treated with a combination of early endotracheal
intubation, followed by the administration of exogenous surfac-
tant and mechanical ventilation (MV).3 Although this approach has
been demonstrated to be lifesaving, tracheal intubation is an
invasive procedure with attendant risks. Of note, prolonged MV
increases the risk of ventilator-associated lung injury, pneumonia,
and bronchopulmonary dysplasia (BPD).4 To minimize the risk of
these complications, the use of non-invasive respiratory support
(NRS), particularly nasal continuous positive airway pressure
(nCPAP), has become a widespread strategy for early respiratory
management of preterm infants. However, a high proportion of
very low-gestational-age infants supported from birth with nCPAP
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still require MV within the first 72 h of life.5 Therefore, the primary
use of NRS and the administration of exogenous surfactant
without MV are major goals for clinicians that remain challenging.
The Intubation–Surfactant administration–Extubation technique,
known as InSurE, is traditionally widespread in neonatal units,
combining the advantages of short intubation and MV with those
of nCPAP and surfactant. More recently, new approaches for bolus
surfactant instillation without concomitant MV have been
described6–9 and have rapidly gained popularity. These strategies
are known as minimally invasive surfactant therapy or less invasive
surfactant administration (LISA). The LISA technique is performed
using the laryngoscope with or without Magill forceps to
introduce a thin catheter through the vocal cords to deliver a
bolus of surfactant while the infant is managed with NRS,
breathing spontaneously. Several clinical studies comparing the
InSurE and LISA have found a decreased need of early MV need
and a decrease in the composite outcome of death and BPD with
LISA.10 Recently, the results of 2 years follow-up from the AMV
(avoid mechanical ventilation) study showed no statistically
significant differences in weight, length, or neurodevelopmental
outcome between the LISA intervention group and the control
group that received CPAP, rescue intubation, and surfactant
treatment if needed.11 Also, remarkable results have been shown
in the NINSAPP trial.12 Given these promising results, LISA is
rapidly being adopted in neonatal intensive care units.13,14
However, the question still remains regarding several aspects of
this technique, highlighting the need for further investigations of
the LISA approach.15,16
The main potential delivery difference between InSurE and LISA
is attributed to the effects of manual or MV and spontaneous
breathing, respectively, on the surfactant bolus, which promotes
its dispersion through the respiratory system. Nevertheless, clinical
data comparing surfactant distribution in the lungs after InSurE or
LISA administration are lacking. Niemarkt et al. compared
surfactant lung deposition in preterm lambs after delivering a
bolus of 200 mg/kg of surfactant (Poractant alfa) either using the
LISA technique or the classic method with surfactant and MV.17
Unfortunately, no InSurE group was included in this study.
Surprisingly, after 180min of follow-up, the intrapulmonary
exogenous surfactant amount was almost sixfold lower in the
group of animals treated with LISA compared to the standard
method.17 Also, Herting and colleagues showed that >30% of the
preterm infants receiving LISA with a gestational age below
27 weeks required MV in the first 72 h following treatment.15 Even
if there is still an ongoing debate on the reasons for this failure
rate, this could be due to the reduced respiratory effort of this
specific population of infants or to an insufficient lung deposition
of the exogenous surfactant.
We have recently established a robust spontaneously breathing
adult rabbit model of RDS to evaluate the acute effects of surfactant
therapy in the context of NRS on pulmonary function through gas
exchange and pulmonary mechanics. In this model, surfactant
depletion by repeated broncho-alveolar lavages (BALs) reduces the
recovered intrapulmonary desaturated-phosphatidylcholine (DSPC)
pool from ~20mg/kg to values <3mg/kg,18 producing a significant
reduction of lung compliance and a permanent gas exchange
impairment if the animals are managed only with NRS.19 However,
this induced respiratory failure can be reverted by the intratracheal
instillation of 200mg/kg of Poractant alfa using InSurE.19,20 After
surfactant treatment by InSurE, the intrapulmonary DSPC pool was
also restored to baseline.18
In the present study, we have used this established model to
compare the efficacy of LISA and InSurE delivery in terms of acute
pulmonary response to surfactant treatment as well as to compare




The experiments were carried out in 6–7-week-old male rabbits
(Charles River Laboratories, Calco, Italy). All experimental proce-
dures were approved by the intramural Animal Welfare Body, and
the Italian Ministry of Health (Prot.no. 1300-2015-PR) and comply
with the European regulations for animal care.
Rabbits (bodyweight of 1.5–2.5 kg) were initially sedated with
intramuscular (i.m.) medetomidine (Domitor®, 2 mg/kg). The
throat of the animals was first shaved, and local anesthesia was
applied in the anterior neck with lidocaine gel (Luan® 2.5%). Thirty
minutes later, the animals received 50mg/kg of ketamine
(Imalgene 1000®, Merial-Boehringer Ingelheim, France) and 5
mg/kg of xylazine (Rompun®, Bayer, Germany) i.m. Rabbits, in the
supine position, were intubated and stabilized on positive
pressure ventilation (Fabian HFO, Acutronic, Zug, Switzerland) as
previously described.18,19,21,22 Fraction of inspired oxygen (FiO2)=
100%, flow= 10 L/min, respiratory rate (RR)= 40 breaths/min,
positive end-expiratory pressure (PEEP)= 3 cmH2O, tidal volume
(VT) targeted to 7mL/kg (with the peak inspiratory pressure (PIP)
not exceeding 15 cmH2O) and inspiratory time of 0.5 s. Airway
flow, mean airway pressure, and VT were monitored as long as the
animals were intubated. Body temperature was constantly
measured with a rectal probe and maintained at 37 °C by placing
a heating pad underneath the animal.
After endotracheal intubation, a catheter was inserted into the
right jugular vein for continuous infusion of 1mg/mL of ketamine
and 0.1mg/mL of xylazine in 0.9% saline solution (100 μL/min) to
maintaining anesthesia at a steady level for the whole experimental
period. Trometamol (tris-hydroxymethyl aminomethane, 1 M, Sigma-
Aldrich) was also infused during the surfactant depletion procedure
for maintaining CO2 level under control. A second catheter was
inserted into the right carotid artery for blood sampling. After
instrumentation, baseline blood gases were measured with a blood
sample analyzer (Radiometer Medical, Denmark). Animals with an
initial arterial oxygen partial pressure (PaO2) value >400mmHg at
PIP <15 cmH2O were included in the study. Spontaneous breathing
was monitored using a multi-parameter monitor (IntelliVue, Philips,
Amsterdam) and evaluating chest movements and continuous vital
parameters (SpO2 and heart rate).
To induce respiratory distress, repeated BALs were performed
by flushing the airways with 20 mL/kg of pre-warmed 0.9% NaCl
solution, followed by a short recovery period in between, until a
PaO2 value <150 mmHg was reached. Then, if after 15 min of
stabilization on MV the respiratory failure was confirmed (PaO2 <
150mmHg, with PIP not exceeding 23 cmH2O), the animal was
included in the study.
Experimental groups
Twenty-six animals were allocated to one of the three experi-
mental groups (figure of the experimental design available
as supplemental material). Animals in the Control group (n = 6)
were maintained on nCPAP (Fabian HFO, Acutronic; 10 cmH2O) for
180min, using customized nasal prongs as an interface. We
selected a CPAP level of 10 cmH2O because it generates a
pharyngeal pressure of 3.9 ± 0.5 cmH2O in our rabbit model (data
not shown), which is in line with the pressures used in clinical
practice. Animals allocated to the InSurE group (n = 10) received
an intratracheal bolus of Poractant alfa (200 mg/kg, Curosurf®
Chiesi Farmaceutici) in the supine position followed by 10min of
MV (VT= 7mL/Kg, RR= 40/min, and PEEP= 3 cmH2O).
23,24 After
that, animals in the InSurE group were managed with nCPAP
(10 cmH2O) for 180 min. Animals in the LISA group (n= 10)
received Poractant alfa (200 mg/kg) using the LISA technique.
With the animal in the supine position and maintained on nCPAP
(10 cmH2O), a nasogastric enteral feeding tube (Penta enteral
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SEGAP®, diameter= 2mm and length= 50 cm) was introduced
into the trachea with direct visualization of the vocal cords with
the videoscope (Ambu® aView™). Briefly, the videoscope tip was
introduced into the oral cavity until the oropharynx could be
visualized in the monitor to obtain an unobstructed view of the
epiglottis and vocal cords ventrally. Once the opening of the vocal
cords was visualized, the catheter was advanced through the
vocal cords and surfactant was instilled. After surfactant admin-
istration, the feeding tube was removed, and animals were
maintained on nCPAP (10 cmH2O) for 180 min (Fig. 1). All animals
were maintained on sedation (continuous infusion of 1 mg/mL of
ketamine and 0.1 mg/mL of xylazine in 0.9% saline solution)
during surfactant treatment and for the whole experimental time.
Gas exchange and respiratory indices
Arterial carbon dioxide and oxygen partial pressure (PaCO2, PaO2)
and pH were measured right after the induction of anesthesia
(baseline) and after the induction of respiratory distress (Radio-
meter Medical, Denmark). Arterial blood gases were also
measured right after the animal was put on nCPAP, 15 and 30
min after the start of nCPAP, and then every 30 min until the end
of the experiment.
PaO2 and PaCO2 were also used to compute the oxygenation
index (OI) and the ventilation efficacy index (VEI). To perform a
direct comparison of the ventilation indices at baseline with the
post surfactant treatment values, animals were shifted from
nCPAP to MV after completion of the 180min observational
period. The brief period of MV (5–10min) was performed
using the same ventilation settings as at baseline (FiO2 100%,
flow= 10 L/min; RR= 40 bpm, PEEP= 3 cmH2O, VT set at 7 mL/kg,
and inspiratory time of 0.5 s. OI and VEI were therefore determined
at those time intervals in which the animals were ventilated with a
tracheal tube: at baseline, after inducing the acute RDS, and at the
end of the 180min follow-up period. The OI was calculated as
follows:
OI ¼ FiO2 MAP  100=PaO2:
The VEI was calculated to evaluate the overall ventilation
efficiency of mechanically ventilated animals independently from
the ventilation settings:
VEI ¼ 3800= PIP=PEEPð ÞRRPaCO2½ :
Pulmonary mechanics
Dynamic compliance (Cdyn) was also determined at those time
intervals in which animals were managed with MV: Cdyn was
calculated dividing lung volume (ΔV) by the changes in pressure
(ΔP) standardized by the animal’s weight.
Cdyn ¼ ΔV= ΔP  weightð Þ:
After autoptic analysis performed to evaluate pneumothorax
events, a post mortem pressure–volume (P/V) curve was
also performed. The lungs were progressively inflated, introdu-
cing 5, 10, 15, 20, 25, and 30 mL of air volume through a syringe.
The pressure recorded at each insufflation volume was
annotated and the lungs were then deflated. The pressure
recorded after the insufflation of 30 mL of air was used as an
endpoint to compare the pulmonary mechanics between the
groups.
Intrapulmonary DSPC quantification
As a proxy for lung deposition of exogenous surfactant, the
intrapulmonary levels of DSPC after 180 min of nCPAP were
determined, as previously described.25 BALs from three animals
per control group and six animals per surfactant-treated groups
were collected as described above, centrifuged, and stored
at −80 °C until analysis. Lipids were extracted according to the
method described by Bligh and Dyer.26 DSPC was separated by
thin-layer chromatography after treatment with osmium tetra-
oxide.27 Fatty acids of DSPC were derivatized as methyl ester by
adding 2mL 3M HCl methanol and extracted with hexane.
Quantitative analysis of DSPC was performed by a FID gas
chromatograph (Agilent 5890, Milan, Italy). Data are presented as
mg/kg of DSPC.
Porcine SP-C lung distribution
Matrix-assisted laser desorption ionization (MALDI) mass spec-
trometry imaging (MSI) technique28–30 was used to investigate
the lung distribution of porcine SP-C deriving from Poractant
alfa administrations (InSurE group, n= 3; LISA group, n= 3).
Fresh-frozen frontal sections of the animal’s left lung lobes were
taken with a cryostat (CM1860 UV, Leica Microsystem, Wetzlar,
Germany) at 20-µm thickness and posed on ITO conductive
glasses (Bruker Daltonics, Bremen, Germany). A 50% ethanol
solution with 0.2% of trifluoroacetic acid, of 2,5-dihydroxyben-
zoic acid in a concentration of 30 g/L, was sprayed all over the
tissue surface with a pneumatic device (IMatrix Spray, Tardo
Gmbh, Switzerland) with an in-house edited method. Instru-
mental analysis was carried out on an Ultraflex III MALDI-Tof/Tof
mass spectrometer (Bruker Daltonics) in positive ion reflector
mode, with full scan acquisition in the mass range 1500–5000
Da, rasterizing the tissue surface every 350 µm in both x and y
directions. Two-dimensional (2D) ion intensity maps were
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Fig. 1 Gas exchange Indices. PaO2 (a) and PaCO2 (b) values in surfactant-depleted adult rabbits treated with nasal continuous positive
pressure ventilation (nCPAP, white squares), Intubation–Surfactant–Extubation plus nCPAP (InSurE, black circles), or plus less invasive
surfactant administration (LISA gray circles). Values are shown as mean ± SEM. †p InSurE and LISA vs. nCPAP <0.01; *p InSurE vs. LISA <0.05.
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SP-C+ H]+ ion at m/z 4188.5 extracted with a tolerance of 1 Da.
Datafiles were exported in the open-source imzML format31 and
individual ion images were extracted by using a custom Python
library relying on the pyimzML parser. All data analyses were
performed in R (https://www.R-project.org). Data normalization
and preprocessing were the same as described by Zecchi et al.32
Briefly, all analyses were performed on the log-transformed MSI
intensity to compensate for the expected heteroscedasticity of
this type of data. An additional step of batch correction was
implemented by setting to zero the average intensity measured
on the background pixels. The two experimental groups were
compared considering the interquartile range (IQR) of the
imaging signal over the frontal sections as a quantitative proxy
of the variability of the distribution of Poractant alfa within the
lungs. Imaging data were also used to reconstruct drug
distribution maps. In this case, the signal obtained for each
animal was mean-centered and scaled in order to allow a direct
comparison of the individual spatial distributions.
Statistical analysis
Group data are presented as mean ± standard error of the mean
(SEM). Raw data were analyzed and compared by repeated-
measures two-way analysis of variance as a function of group and
time, followed by Dunnett’s and Tukey’s t post hoc tests
(GraphPad software, version 6.0). p value <0.05 was considered
statistically significant. In the MALDI-MSI experiments, the two
experimental groups were compared considering the IQR of the
imaging signal over the frontal sections as a quantitative proxy of
the variability of the distribution of Poractant alfa within the lungs;
the statistical comparison was performed by applying a standard
Welch two-sample t test.
RESULTS
No significant differences were found between groups in PaO2,
PaCO2, pH, or Cdyn at baseline. The rabbits’ bodyweight and the
number of BALs required to induce severe and sustained
respiratory distress did not differ among the groups (Table 1).
Gas exchange and ventilator indices
The series of BALs produced a marked and significant impairment
of gas exchange resulting in poor arterial oxygenation (mean
PaO2 < 70mmHg in all the groups) and a marked increase of
arterial carbon dioxide (mean PaCO2 > 70mmHg in all the groups).
The successful endogenous surfactant depletion was persistent, as
denoted by the sustained impairment of gas exchange in the
untreated control group (Fig. 1).
Surfactant administration significantly improved PaO2. Regard-
less of the surfactant administration method, significant differ-
ences were registered at 15 min between the surfactant-treated
groups and untreated control animals (p < 0.01), and these
differences lasted for the whole experimental period (Fig. 1a).
However, the increase in oxygenation was faster in the InSurE
group compared to the LISA group, as highlighted by a significant
difference between groups at 15–120 min (p < 0.05). PaCO2
remained high in all the groups. It remained fairly constant in
the control and LISA groups but increased in the InSurE group
following surfactant administration. The InSurE group registered
the highest mean PaCO2 at all study points and was even
significantly higher in comparison to the LISA group at 120, 150,
and 180 min (p < 0.05, Fig. 1b).
The mean OI increased from 1.2 ± 0.2 to 15.7 ± 4.3 after
depleting the endogenous surfactant (mean ± SD of all animals).
OI values returned to baseline values after surfactant treatment,
Table 1. Baseline characteristics of the experimental groups.
Group Bodyweight (kg) PaO2 (mmHg) PaCO2 (mmHg) pH Cdyn (mL/cmH2O/kg) Number of BALs
Control 1.86 ± 0.1 494 ± 12 55 ± 5 7.45 ± 0.03 0.97 ± 0.06 9.5 ± 0.8
InSurE 1.71 ± 0.1 451 ± 15 53 ± 3 7.49 ± 0.03 1.01 ± 0.08 8.2 ± 0.8
LISA 1.83 ± 0.1 467 ± 15 53 ± 3 7.49 ± 0.01 0.93 ± 0.08 9.4 ± 1.0
Mean ± SEM are displayed.
PaO2 arterial oxygen partial pressure, PaCO2 arterial carbon dioxide partial pressure, Cdyn dynamic compliance, BAL broncho-alveolar lavage, InSurE






































































Fig. 2 Oxygenation Indices. Box plots showing a the oxygenation index (OI) and b the ventilation efficacy index (VEI) at baseline (from all
animals), after inducing respiratory distress (Post BALs, from all animals) and 180min after treatment with nasal continuous positive pressure
ventilation (nCPAP, Control), with Intubation–Surfactant–Extubation plus nCPAP (InSurE), or nCPAP plus with less invasive surfactant
administration (LISA). The boxes encompass the 25–75 percentiles. The horizontal line within the boxes represents the median and the black
dot the mean of each group. The whiskers indicate the maximum and minimum values observed for each group. †p vs. Control <0.01.
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achieving mean OI values of 2.0 ± 0.8 and 2.3 ± 0.2 for the InSurE
and LISA groups, respectively (Fig. 2a). OI values partially
recovered after 180 min of nCPAP in the control group. Never-
theless, the mean OI value of the control group (8.0 ± 5.5)
was significantly higher compared to the surfactant-treated
groups (p < 0.01).
The increase of the OI was mirrored by a decrease of the VEI
from 0.25 ± 0.05, at baseline, to 0.06 ± 0.01 in ±SD of all animals.
Surfactant treatment, in particular, if delivered by the LISA
method, slightly improved the mean VEI, although the mean
values in all the groups were significantly lower compared to
those recorded at baseline (Fig. 2b).
Lung mechanics
Surfactant depletion produced almost a 70% drop of Cdyn, from
0.97 ± 0.22 to 0.31 ± 0.10 mL/cmH2O/kg (mean ± SD of all animals).
Cdyn improved in all the groups after the observational period.
After 180min, the highest mean Cdyn was registered in the LISA
group (0.65 ± 0.29 mL/cmH2O/kg) followed by the InSurE and
control groups (0.61 ± 0.17 and 0.48 ± 0.13 mL/cmH2O/kg, respec-
tively, Fig. 3a). No significant differences were detected between
the groups. Before P/V curve measurement, we performed an
autoptic analysis and we did not report any pneumothorax events.
The P/V curve revealed stiffer lungs in the control group
compared to surfactant-treated animals (Fig. 3b). The mean
pressure registered after insufflating 30mL of air into the lungs
was significantly lower in the LISA and InSurE groups (20 ± 1.4
and 19.0 ± 2.1 cm H2O) compared to the control group (23.5 ±
2.5 cmH2O, p < 0.05).
Intrapulmonary DSPC quantification
A marginal DSPC signal was detected in untreated control animals
(1.20 ± 0.51 mg/kg, Fig. 4). The mean intrapulmonary amount of
DSPC detected in the surfactant-treated groups was significantly
higher (p < 0.01) compared to untreated animals. No significant
differences in terms of intrapulmonary DSPC amount were
recorded between the InSurE (39.1 ± 3.5 mg/kg) and LISA groups
(35.5 ± 6.3 mg/kg).
SP-C lung distribution
The comparison of the IQR ranges between the study groups is
shown in Fig. 5. The plot indicates that the two administration
strategies give comparable results in terms of signal variability
across the sections (p value= 0.30).
The absence of a strong difference between the two delivery
methods is also supported by the visual inspection of the porcine
SP-C distribution maps reconstructed from the MALSI-MSI imaging
data. An example of the maps is shown in Fig. 6.
For both treatments, sparse high-intensity areas (yellow) are
distributed over the lung parenchyma, which is characterized by
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Fig. 3 Lung Mechanics. a Box plots showing the dynamic compliance (Cdyn) at baseline (from all animals), after inducing respiratory distress
(Post BALs, from all animals) and 180min after treatment with nasal continuous positive pressure ventilation (nCPAP, Control), with
Intubation–Surfactant–Extubation (InSurE), or with less invasive surfactant administration (LISA). The boxes encompass the 25–75 percentiles.
The horizontal line within the boxes represents the median and the black dot the mean of each group. The whiskers indicate the maximum
and minimum values observed for each group. b Bar chart showing the mean pressure values recorded after insufflating 30mL of air post
mortem in the lungs of animals managed with nCPAP only, control, treated with Intubation–Surfactant–Extubation plus nCPAP (InSurE), or

















Fig. 4 Intrapulmonary DSPC quantity. Bar chart showing the
intrapulmonary amount of disaturated-phosphatidylcholine (DSPC)
in the lungs of animals managed with nasal continuous positive
pressure ventilation (nCPAP, Control), treated with Intubation–
Surfactant–Extubation plus nCPAP (InSurE), or with nCPAP plus
less invasive surfactant administration (LISA). Values are displayed as


















Fig. 5 Comparison of the interquartile range (IQR) of the
normalized MALDI-MSI signal for LISA and InSurE (n= 3 animals
in each group). The bars highlight the position of the mean value
and the dark dots represent data from individual animals. The two
treatments are not significantly different (p= 0.30).
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expected, low-intensity regions are visible in correspondence of
the bronchial tubes.
DISCUSSION
To our knowledge, this is the first study comparing LISA and
InSurE concurrently in terms of oxygenation, lung mechanics,
intrapulmonary surfactant availability, and distribution in a
surfactant-depleted adult rabbit model.
Our study showed a similar 3-h recovery outcome in terms of
oxygenation and lung mechanics in the LISA and InSurE groups.
However, we found a relevant difference in the acute physiolo-
gical response between these two techniques. InSurE was
associated with an acute increase of arterial oxygenation,
whereas PaO2 improved gradually after LISA. The different acute
responses may be related to the use of MV after delivering the
surfactant bolus. Animals allocated in the InSurE group received
treatment followed by 10min of MV, whereas the animals in the
LISA group were managed with nCPAP during surfactant
treatment. These data are in accordance with the results of
Niemarkt et al. who reported a rapid increase of PaO2 values in
intubated and mechanically ventilated lambs compared with the
lambs that underwent LISA and were supported with nCPAP.17
Conversely, this difference in the acute response between LISA
and InSurE was not observed in a similar recent study by Rey-
Santano et al. conducted in surfactant-deficient newborn piglets,
which can be partially explained by the fact that animals in the
InSurE group were mechanically ventilated just for 1 min.33
Three hours after surfactant treatment, both surfactant delivery
methods showed a significant increase of the intrapulmonary
DSPC pool, highlighting the efficacy of the LISA procedure in
surfactant deposition into the lungs. In this regard, our findings
are not fully in line with Niemarkt’s study,17 who showed a
significantly lower surfactant deposition in the lungs of lambs
treated with LISA plus nCPAP compared with the animals treated
with surfactant and MV. The authors speculated that the low
intrapulmonary levels of surfactant might have been caused by
surfactant reflux observed in some animals. This difference in lung
surfactant deposition observed in the present work compared
with the Niemarkt’s study may be explained by the duration of the
LISA procedure in our protocol, which was extended to 2min to
reduce the surfactant reflux, compared to 1-min delivery in
Niemarkt’s study.17 Moreover, we used a video laryngoscope to
minimize the risk of incorrect surfactant delivery.
Notably, we found an amount of DSPC in the lungs of animals
treated with LISA not significantly different from the amount
detected in the InSurE group. Giambelluca et al. determined that
the BAL-recovered mean DSPC pool in the lungs of healthy
adult rabbits ranged between 15 and 25mg/kg, whereas in rabbits
with severe respiratory distress the mean DSPC was <2mg/kg.18
According to these findings, the mean DSPC pool observed in the
LISA group after 180min of nCPAP (36.4 ± 6.39 mg/kg) resembles
that of InSurE-treated and healthy rabbits and explains the
significant improvement at 3 h in arterial oxygenation to the same
level of the InSurE group. The preliminary MALDI-MSI findings at 3
h showing a quite extended distribution of exogenous SP-C in the
“D” sections of the lung parenchyma, although obtained in small
numbers of animals, provide a further qualitative explanation for
the comparable arterial oxygenation recovery between the two
groups.
We observed differences in the pharmacodynamics of surfac-
tant therapy, in particular in terms of gas exchange, between LISA
and InSurE. Due to the pushing effect of the ventilator, PaO2
rapidly increased in the InSurE group. We also registered a marked
increase in the mean PaCO2 immediately after surfactant
administration in this group. Similarly, Rey-Santano et al. also
reported a hypercarbia phenomenon in preterm lambs immedi-






Fig. 6 Representative distribution of the porcine SP-C signal in a frontal lung section for InSurE and LISA. The image displays the
normalized5 and scaled raw MALDI-MSI signal.
Surfactant lung delivery with LISA and InSurE in adult rabbits with. . .
F Ricci et al.
6
Pediatric Research _#####################_
the increase of PaCO2 to temporary airway obstruction due to the
acute airway fluid load following surfactant instillation. In our
study, the increase of PaCO2 was not limited to the immediate
period following surfactant instillation, but it lasted until the end
of the experiment in the InSurE group. We might hypothesize that
the surfactant distribution process in the lungs could potentially
be more physiological during the LISA procedure, since sponta-
neous breathing, supported by nCPAP, is the only driver for
surfactant spreading. Moreover, a slower increase in oxygenation
might reduce the risk of oxygen radical production, especially
when FiO2 titration becomes challenging due to acute changes in
arterial oxygenation. In this regard, the risk of multi-organ
damages related to hyperoxia is well known in preterm
infants.35,36
The present study has some limitations. First, we used
surfactant-depleted adult rabbits instead of a preterm animal
model with RDS. In this regard, the surfactant-depleted adult
rabbit model does not present all the features of prematurity-
related RDS. Second, we used customized nasal prongs, which
have not been designed for the rabbit’s nostrils and may therefore
enhance the risk for increased resistance and lead to gas
exchange imbalances, in particular in terms of PaCO2, which
remained high in all the groups despite surfactant treatment.
Moreover, although we monitored that the spontaneous breath-
ing remained effective during and after the whole procedure, the
animals were under sedation. Finally, although we were able to
study the overall intrapulmonary DSPC amount recovered from
BALs and to have a preliminary evaluation of exogenous SP-C
distribution in 2D longitudinal lung sections at the 3-h sacrifice
point, we could not follow the regional distribution of exogenous
surfactant within the lungs in real time, in the time frame
encompassing treatment (t0) to sacrifice (t180min), which should be
addressed in future studies.
CONCLUSIONS
Surfactant administration by the LISA procedure to sponta-
neously breathing, surfactant-depleted adult rabbits was effec-
tive as the InSurE technique in improving pulmonary function in
a 3-h post-treatment time frame. Both methods allowed for a
partially homogeneous intrapulmonary surfactant distribution
and restored the intrapulmonary DSPC pools. Although oxyge-
nation recovery was faster with InSurE, a comparable improve-
ment in oxygenation was observed with LISA. These findings
support the LISA procedure as a valid alternative to the InSurE
technique for surfactant administration. Nevertheless, further
studies are needed to confirm these results in preterm infants
with RDS.
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